The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes. A universal cell line includes cells such as universal chondrocytes that are not immunogenic or allergenic and can be grown in products suitable for use in a number of different people. Use of the universal chondrocytes allows for new processes and products. Where prior art autologous neocartilage constructs required many small reactors (e.g., at least one culture dish per patient to grow one 34 mm disc per patient), using a universal cell line allows, for example, one large batch of cartilage or neocartilage to be made under uniform conditions.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

The present invention relates to a new method for treating human or animal tissue such as cartilage, particularly damaged tissue. More specifically, the invention relates to a method to obtain material for treating the damaged tissue, for example any cartilage damage, in particular as a result of traumatic or degenerative cartilage damage.

Provided is a magnetically actuated microscaffold for minimal invasive osteochondral regeneration. More particularly, provided is a composition for cartilage regeneration, a microscaffold for cartilage regeneration, in which magnetic particles and cartilage regeneration cells are loaded on the surface of or within a 3-dimensional porous microstructure composed of a biodegradable polymer and having a diameter of 200-300 μm; and a microscaffold for bone regeneration, in which magnetic particles and bone regeneration cells are loaded on the surface of or within a 3-dimensional porous microstructure composed of a biodegradable polymer and having a diameter of 700-900 μm.

Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers.

The present invention relates to a tissue substitute material for implantation, comprising (a) a substrate to be implanted covered with (b) a controlled release coating containing (c) at least one biologically substance that decreases bacterial growth, wherein the (b) controlled release coating is a bioavailable, biocompatible polymer material and wherein the (c) at least one biologically active substance that decreases bacterial growth. The present invention also relates to a method to prepare the tissue substitute material, as wells the uses thereof.

This invention provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates comprise a marine organism skeletal derivative and are characterized by a specific fluid uptake capacity value of less than 40%, processes for selection of the same and applications of the same. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates are characterized by having a contact angle value of more than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate is characterized by a minimal surface roughness (Ra) or substantial surface smoothness, as measured by scanning electron microscopy or atomic force microscopy. The invention also provides processes for selection of an optimized coral-based solid substrate.

The invention provides a method of producing a connective tissue graft suitable for correcting a connective tissue defect, comprising determining the size and shape of a tissue defect, obtaining a fat tissue from a patient modelled to fit the size and shape of the tissue defect, contacting the fat tissue with one or more connective tissue specific growth or differentiation factors; and kits for such a method.

A fresh tissue allograft having at least one tissue portion maintained above a predetermined temperature to reduce the rate of cell death. A storage media having at least one free-radical scavenger is applied to the allograft to further slow the rate of cell death.